Patents by Inventor Darwin J. Prockop
Darwin J. Prockop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100278790Abstract: The present invention provides compositions comprising mesenchymal stem cells (MSCs), and methods for their novel use in the repair of cardiac damage and treatment of inflammatory diseases. The invention also provides methods for using TSG-6 protein that is secreted by MSCs under certain conditions, for repair of cardiac damage and inflammatory disease. The compositions of the invention may be particularly useful in restoring cardiac function following cardiac damage, including, but not limited to, myocardial infarction, as well as in reducing symptoms of inflammatory disease.Type: ApplicationFiled: June 18, 2009Publication date: November 4, 2010Inventors: Darwin J. Prockop, Ryang Hwa Lee
-
Publication number: 20100247494Abstract: The present invention encompasses an osteogenic composition comprising mesenchymal stem cells pre-cultured in the presence of an agent that accelerates canonical Wnt signaling therein. Also, provided are osteogenic compositions incorporated into a biocompatible gel. The present invention provides methods for treating bone degeneration or injury associated with a pathophysiological condition in a mammal or for accelerating repair of a skeletal injury in a mammal by administering to the mammal or contacting the site of injury with the osteogenic composition.Type: ApplicationFiled: March 23, 2010Publication date: September 30, 2010Applicant: The Texas A&M University SystemInventors: Carl A. Gregory, Darwin J. Prockop
-
Publication number: 20100008964Abstract: Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed.Type: ApplicationFiled: March 4, 2009Publication date: January 14, 2010Applicant: THOMAS JEFFERSON UNIVERSITYInventors: Darwin J. Prockop, Ruth F. Pereira, Dennis B. Leeper, Michael D. O'Hara, Joseph Kulkosky, Donald Phinney, Alexey Laptev, Jose Caro
-
Publication number: 20090214492Abstract: Methods of treating a human patient having a disease, disorder or condition of the central nervous system are disclosed. The methods include obtaining a bone marrow sample from a human donor, isolating stromal cells from the bone marrow sample, and administering the isolated stromal cells to the central nervous system of the human patient, wherein the presence of the isolated stromal cells in the brain effects treatment of the disease, disorder or condition. Stromal cells which are isolated may be cultured in vitro, they may be genetically engineered to produce therapeutic compounds, and/or they may be pre-differentiated prior to administration into the central nervous system.Type: ApplicationFiled: January 20, 2009Publication date: August 27, 2009Applicant: PHILADELPHIA HEALTH AND EDUCATION CORPORATIONInventors: Darwin J. Prockop, David G. Stokes, S. Ausim Azizi
-
Patent number: 7547545Abstract: The invention relates to methods for inducing marrow stromal cells to differentiate into neural cells by way of increasing intracellular levels of cyclic AMP. The invention also encompasses methods of producing a neural cell by causing a marrow stromal cell to differentiate into a neural cell by increasing intracellular levels of cyclic AMP. Methods for treating a human patient in need of neural cells are also disclosed, as well as methods for treating a human patient having a disease, condition, or disorder of the central nervous system.Type: GrantFiled: July 12, 2006Date of Patent: June 16, 2009Inventors: Darwin J. Prockop, Weiwen Deng
-
Publication number: 20090035347Abstract: Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed.Type: ApplicationFiled: March 6, 2008Publication date: February 5, 2009Applicant: THOMAS JEFFERSON UNIVERSITYInventors: Darwin J. Prockop, Ruth F. Pereira, Dennis B. Leeper, Michael D. O'Hara, Joseph Kulkosky, Donald Phinney, Alexey Laptev, Jose Caro
-
Publication number: 20080299097Abstract: Multipotent stromal cells “MSCs” have been described as consisting of at least two populations of cells, rapidly self-renewing stem cells (RS-MSCs), and larger, slowly replicating cells (mMSCs). The present invention provides methods for enhancing engraftment of MSCs in vivo by administering an enriched fraction of RS-MSCs that express certain cell surface markers.Type: ApplicationFiled: November 8, 2007Publication date: December 4, 2008Applicant: Tulane University Health Sciences CenterInventors: Darwin J. Prockop, Ryang Hwa Lee
-
Publication number: 20080131407Abstract: The present invention relates to methods of inducing differentiation of mammalian bone marrow stromal cells into neuronal cells by contacting marrow stromal cells with a neuronal differentiation-inducing compounds. Neuronal differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, dimethylfumarate, and n-acetylcysteine. Once induced to differentiate into neuronal cells, the cells can be used for cell therapy, gene therapy, or both, for treatment of diseases, disorders, or conditions of the central nervous system.Type: ApplicationFiled: September 4, 2007Publication date: June 5, 2008Applicants: PHILADELPHIA HEALTH AND EDUCATION CORPORATION, UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Ira B. Black, Dale L. Woodbury, Darwin J. Prockop, Emily Schwarz
-
Patent number: 7374937Abstract: The invention includes in vitro methods of inducing and enhancing proliferation of human marrow stromal cells for use in, for example, gene therapy and transplantation methods. The invention also includes a method of assessing the expandability (i.e., proliferative capacity) of human marrow stromal cells. In addition, the invention includes a conditioned medium for enhancing proliferation of human marrow stromal cells.Type: GrantFiled: October 25, 2000Date of Patent: May 20, 2008Assignee: Philadelphia Health and Education CorporationInventors: Darwin J. Prockop, David Colter, Carla DiGirolamo
-
Publication number: 20080102058Abstract: The invention relates to the use of marrow stromal cells to enhance hematopoiesis in a mammal.Type: ApplicationFiled: May 22, 2007Publication date: May 1, 2008Applicant: PHILADELPHIA HEALTH AND EDUCATION CORPORATIONInventors: Darwin J. Prockop, Russell G. Reiss, John Langell
-
Patent number: 7279331Abstract: The present invention relates to methods of inducing differentiation of mammalian bone marrow stromal cells into neuronal cells by contacting marrow stromal cells with a neuronal differentiation-inducing compounds. Neuronal differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, dimethylfumarate, and n-acetylcysteine. Once induced to differentiate into neuronal cells, the cells can be used for cell therapy, gene therapy, or both, for treatment of diseases, disorders, or conditions of the central nervous system.Type: GrantFiled: August 6, 2002Date of Patent: October 9, 2007Assignees: Philadelphia Health and Education Corporation, University of Medicine and Dentistry of New JerseyInventors: Ira B. Black, Dale L. Woodbury, Darwin J. Prockop, Emily Schwarz
-
Patent number: 7056738Abstract: Marrow stromal cells (MSCS) are adult stem cells from bone marrow that can differentiate into multiple non-hematopoietic cell lineages. Colonies of human MSCs were shown to contain both small, rapidly self-renewing stem cells (RS cells) and large, more mature cells (mMSCs). Samples enriched for RS cells had a greater potential for multipotential differentiation than samples enriched for mMSCs. Also, RS cells have a series of surface epitopes and expressed proteins that can be used to differentiate RS cells from mMSCs. The results suggest that it will be important to distinguish the two major sub-populations of MSCs in defining their biology and their potentials for cell and gene therapy.Type: GrantFiled: March 23, 2001Date of Patent: June 6, 2006Assignees: Tulane University, Philadelphia Heath and Education CorporationInventors: Darwin J. Prockop, David C. Colter, Ichiro Sekiya
-
Patent number: 7018803Abstract: The invention relates to peptides and peptidomimetics which inhibit assembly of human type I collagen. Methods of identifying such peptides and peptidomimetics are also included in the invention.Type: GrantFiled: October 24, 2002Date of Patent: March 28, 2006Assignee: Drexel University College of MedicineInventors: Darwin J. Prockop, Andrzej Fertala
-
Patent number: 6974571Abstract: Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed.Type: GrantFiled: March 28, 1996Date of Patent: December 13, 2005Assignee: Thomas Jefferson UniversityInventors: Darwin J. Prockop, Ruth F. Pereira, Dennis B. Leeper, Michael D. O'Hara, Joseph Kulkosky, Donald Phinney, Alexey Laptev
-
Publication number: 20040208861Abstract: The invention relates to the use of marrow stromal cells to enhance hematopoiesis in a mammal.Type: ApplicationFiled: May 12, 2004Publication date: October 21, 2004Applicant: Philadelphia Health and Education CorporationInventors: Darwin J. Prockop, Russell G. Reiss, John Langell
-
Publication number: 20040166097Abstract: Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed.Type: ApplicationFiled: February 26, 2004Publication date: August 26, 2004Applicant: Thomas Jefferson UniversityInventors: Darwin J. Prockop, Ruth F. Pereira, Dennis B. Leeper, Michael D. O'Hara, Joseph Kulkosky, Donald Phinney, Alexey Laptev, Jose Caro
-
Publication number: 20040091464Abstract: Methods of treating a human patient having a disease, disorder or condition of the central nervous system are disclosed. The methods include obtaining a bone marrow sample from a human donor, isolating stromal cells from the bone marrow sample, and administering the isolated stromal cells to the central nervous system of the human patient, wherein the presence of the isolated stromal cells in the brain effects treatment of the disease, disorder or condition. Stromal cells which are isolated may be cultured in vitro, they may be genetically engineered to produce therapeutic compounds, and/or they may be pre-differentiated prior to administration into the central nervous system.Type: ApplicationFiled: June 27, 2003Publication date: May 13, 2004Applicant: Philadelphia Health & Education CorporationInventors: Darwin J. Prockop, David G. Stokes, S. Ausim Azizi
-
Patent number: 6653134Abstract: Methods of treating a human patient having a disease, disorder or condition of the central nervous system are disclosed. The methods include obtaining a bone marrow sample from a human donor, isolating stromal cells from the bone marrow sample, and administering the isolated stromal cells to the central nervous system of the human patient, wherein the presence of the isolated stromal cells in the brain effects treatment of the disease, disorder or condition. Stromal cells which are isolated may be cultured in vitro, they may be genetically engineered to produce therapeutic compounds, and/or they may be pre-differentiated prior to administration into the central nervous system.Type: GrantFiled: February 24, 1998Date of Patent: November 25, 2003Assignee: CP Hahnemann UniversityInventors: Darwin J. Prockop, David G. Stokes, S. Ausim Azizi
-
Publication number: 20030203484Abstract: The present invention relates to methods of inducing differentiation of mammalian bone marrow stromal cells into neuronal cells by contacting marrow stromal cells with a neuronal differentiation-inducing compounds. Neuronal differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, dimethylfumarate, and n-acetylcysteine. Once induced to differentiate into neuronal cells, the cells can be used for cell therapy, gene therapy, or both, for treatment of diseases, disorders, or conditions of the central nervous system.Type: ApplicationFiled: August 6, 2002Publication date: October 30, 2003Applicants: Philadelphia Health And Education Corporation, University of Medicine and Dentistry of New JerseyInventors: Ira B. Black, Dale L. Woodbury, Darwin J. Prockop, Emily Schwarz
-
Publication number: 20030202966Abstract: Methods of treating patients who are suffering from a disease, disorder or condition characterized by a bone cartilage or lung defect are disclosed. The methods comprising the step of intravenous administration of stromal cells isolated from normal syngeneic individuals or intravenous administration of stromal cells isolated from the patient subsequent to correction of the genetic defect in the isolated cells. Implant devices comprising a container that has at least one membrane surface and stromal cells isolated from bone marrow that comprise a gene construct are disclosed. The gene construct in the stromal cells comprises a nucleotide sequence that encodes a beneficial protein operably linked to regulatory elements which function in stromal cells. Methods of treating individuals with diseases, disorders or conditions which can be treated with a beneficial protein, including diseases, disorders or conditions characterized by gene defects are disclosed.Type: ApplicationFiled: April 25, 2003Publication date: October 30, 2003Applicant: Thomas Jefferson UniversityInventors: Darwin J. Prockop, Ruth F. Pereira, Dennis B. Leeper, Michael D. O'Hara, Joseph Kulkosky, Donald Phinney, Alexey Laptev, Jose Caro